NCT01048645View on ClinicalTrials.gov

Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

November 30, 2009

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

ATRA

Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin

OTHER

PLACEBO

Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin

Trial Locations (1)

14080

National Institute of Cancerología, Mexico City

All Listed Sponsors
collaborator

Instituto Nacional de Enfermedades Respiratorias

OTHER_GOV

lead

National Institute of Cancerología

OTHER_GOV

NCT01048645 - Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter